Cargando…
Non-Clinical Safety Pharmacology Evaluations of Trazpiroben (TAK-906), a Novel Dopamine D(2)/D(3) Selective Receptor Antagonist for the Management of Gastroparesis
BACKGROUND: Gastroparesis is characterized by delayed gastric emptying in the absence of mechanical obstruction. Owing to the potential for serious side effects, current treatments have restrictions on their use and there is a need for novel compounds with favorable safety profiles. Trazpiroben (pre...
Autores principales: | Kreckler, Laura, Osinski, Mark, Williams, Scott, Whiting, Roger |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842350/ https://www.ncbi.nlm.nih.gov/pubmed/35173492 http://dx.doi.org/10.2147/JEP.S332715 |
Ejemplares similares
-
Evaluation of the pharmacokinetics of trazpiroben (TAK‐906) in the presence and absence of the proton pump inhibitor esomeprazole
por: Kaur Mukker, Jatinder, et al.
Publicado: (2022) -
Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK‐906), a Novel Selective D(2)/D(3) Receptor Antagonist: A Phase 1 Randomized, Placebo‐Controlled Single‐ and Multiple‐Dose Escalation Study in Healthy Participants
por: Whiting, Roger L., et al.
Publicado: (2021) -
Evaluation of the Pharmacokinetics of Trazpiroben (TAK-906), a Peripherally Selective D(2)/D(3) Dopamine Receptor Antagonist, in the Presence and Absence of Itraconazole, a Potent CYP 3A4 Inhibitor
por: Chen, Chunlin, et al.
Publicado: (2021) -
The pharmacokinetics of oral trazpiroben (TAK‐906) after organic anion transporting polypeptide 1B1/1B3 inhibition: A phase I, randomized study
por: Mukker, Jatinder K., et al.
Publicado: (2022) -
Evaluating the Safety, Tolerability, and Disposition of Trazpiroben, a D(2)/D(3) Receptor Antagonist: Phase I Single‐ and Multiple‐Ascending Dose Studies in Healthy Japanese Participants
por: Yamaguchi, Takayoshi, et al.
Publicado: (2021)